|
|
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.
Number of employees : 300 people.
|
|
|
| 2020 | 2021 | Delta | | Therapeutic Drugs | 50.12 | 100% | 45.61 | 100% | -9% |
| USD in Million |
|
|
|
| 2021 | | United States | 45.49 | 99.7% |
| Other | 0.12 | 0.3% |
| USD in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
141,741,580 |
132,766,370 |
93.7% |
0 |
0.0% |
93.7% |
|
|
|
| Name | Equities | % | | ILJIN Holdings Co., Ltd. | 6,832,320 |
4.82% | | Fidelity Management & Research Co. LLC | 5,291,226 |
3.74% | | Consonance Capital Management LP | 4,621,325 |
3.26% | | NEA Management Co. LLC | 3,969,834 |
2.80% | | OrbiMed Advisors Private Equity | 3,714,404 |
2.62% | | APG Asset Management NV | 3,450,357 |
2.44% | | Polar Capital LLP | 3,312,723 |
2.34% | | Morgan Stanley & Co. LLC | 2,597,187 |
1.83% | | Bellevue Asset Management AG | 2,405,825 |
1.70% | | Susquehanna Financial Group LLLP | 1,923,005 |
1.36% |
|
| Company contact information |
|
Aurinia Pharmaceuticals, Inc. 4464 Markham Street Suite 1203 Victoria, BC V8Z 7X8 Phone : +1.250.744.2487 Fax : +1.250.744.2498 Web : http://www.auriniapharma.com |
|
|
Sector Bio Therapeutic Drugs
| | 1st jan. | Capi. (M$) |
 | AURINIA PHARMACEUTICALS INC. | -50.55% | 1 603 |
| | | |
| GILEAD SCIENCES, INC. | -11.38% | 80 715 |
| REGENERON PHARMACEUTICALS, INC. | 8.63% | 73 916 |
| VERTEX PHARMACEUTICALS | 22.26% | 68 665 |
 | WUXI APPTEC CO., LTD. | -22.20% | 40 017 |
| BIONTECH SE | -40.07% | 37 546 |
 | GENMAB A/S | -19.24% | 20 071 |
 | ARGENX SE | -6.79% | 17 228 |
| BEIGENE, LTD. | -54.60% | 12 690 |
| NEUROCRINE BIOSCIENCES, INC. | -0.67% | 8 086 |
| HALOZYME THERAPEUTICS, INC. | 11.46% | 6 175 |
| SAREPTA THERAPEUTICS, INC. | -23.55% | 6 024 |
| LEGEND BIOTECH CORPORATION | -16.26% | 6 020 |
| EXELIXIS, INC. | -3.17% | 5 677 |
| INTRA-CELLULAR THERAPIES, INC. | 8.83% | 5 373 |
 | BIOCON LIMITED | -9.67% | 5 052 |
| ASCENDIS PHARMA A/S | -32.73% | 5 050 |
| MARAVAI LIFESCIENCES HOLDINGS, INC. | -18.59% | 4 487 |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | -22.70% | 3 716 |
| ARROWHEAD PHARMACEUTICALS, INC. | -49.02% | 3 574 |
 | PHARMAESSENTIA CORPORATION | 21.84% | 3 386 |
Connections : Aurinia Pharmaceuticals Inc. |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
